Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zifang Guo

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Obesity (Silver Spring, Md.)|October 31, 2009
The relationship of ectopic lipid accumulation to cardiac and vascular function in obesity and metabolic syndromeFrederick L Ruberg, Zhongjing Chen, Ning Hua, et al.
Clinical Pharmacology in Drug Development|June 8, 2019
Pharmacokinetic Interactions Between the Fixed-Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult ParticipantsHwa-Ping Feng, Zifang Guo, Christine Fandozzi, et al.
Pharmacogenomics|June 29, 2019
The pharmacogenetics of OATP1B1 variants and their impact on the pharmacokinetics and efficacy of elbasvir/grazoprevirZifang Guo, Luzelena Caro, Michael N Robertson, et al.
European Journal of Clinical Pharmacology|February 25, 2017
No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrelWilliam L Marshall, Hwa-Ping Feng, Luzelena Caro, et al.
Obesity (Silver Spring, Md.)|September 26, 2009
Mice deficient in phosphofructokinase-M have greatly decreased fat storesLisa Getty-Kaushik, Jason C Viereck, Jessie M Goodman, et al.
Clinical Drug Investigation|February 2, 2021
Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy AdultsLuzelena Caro, Thomayant Prueksaritanont, Christine M Fandozzi, et al.
The Journal of Antimicrobial Chemotherapy|December 13, 2018
Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravirHwa-Ping Feng, Zifang Guo, Lisa L Ross, et al.
Antimicrobial Agents and Chemotherapy|September 27, 2017
Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease InhibitorLuzelena Caro, Larissa Wenning, Zifang Guo, et al.
Clinical and Translational Science|July 25, 2018
No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist TherapyHwa-Ping Feng, Zifang Guo, Luzelena Caro, et al.
Clinical Pharmacology in Drug Development|June 8, 2019
Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct-Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse-Transcriptase Inhibitor Tenofovir Disoproxil FumarateHwa-Ping Feng, Zifang Guo, Luzelena Caro, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Obesity (Silver Spring, Md.)|October 31, 2009
The relationship of ectopic lipid accumulation to cardiac and vascular function in obesity and metabolic syndromeFrederick L Ruberg, Zhongjing Chen, Ning Hua, et al.
Clinical Pharmacology in Drug Development|June 8, 2019
Pharmacokinetic Interactions Between the Fixed-Dose Combinations of Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine and Elbasvir/Grazoprevir in Healthy Adult ParticipantsHwa-Ping Feng, Zifang Guo, Christine Fandozzi, et al.
Pharmacogenomics|June 29, 2019
The pharmacogenetics of OATP1B1 variants and their impact on the pharmacokinetics and efficacy of elbasvir/grazoprevirZifang Guo, Luzelena Caro, Michael N Robertson, et al.
European Journal of Clinical Pharmacology|February 25, 2017
No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrelWilliam L Marshall, Hwa-Ping Feng, Luzelena Caro, et al.
Obesity (Silver Spring, Md.)|September 26, 2009
Mice deficient in phosphofructokinase-M have greatly decreased fat storesLisa Getty-Kaushik, Jason C Viereck, Jessie M Goodman, et al.
Clinical Drug Investigation|February 2, 2021
Evaluation of Pharmacokinetic Drug Interactions of the Direct-Acting Antiviral Agents Elbasvir and Grazoprevir with Pitavastatin, Rosuvastatin, Pravastatin, and Atorvastatin in Healthy AdultsLuzelena Caro, Thomayant Prueksaritanont, Christine M Fandozzi, et al.
The Journal of Antimicrobial Chemotherapy|December 13, 2018
Assessment of drug interaction potential between the HCV direct-acting antiviral agents elbasvir/grazoprevir and the HIV integrase inhibitors raltegravir and dolutegravirHwa-Ping Feng, Zifang Guo, Lisa L Ross, et al.
Antimicrobial Agents and Chemotherapy|September 27, 2017
Effect of Hepatic Impairment on the Pharmacokinetics of Grazoprevir, a Hepatitis C Virus Protease InhibitorLuzelena Caro, Larissa Wenning, Zifang Guo, et al.
Clinical and Translational Science|July 25, 2018
No Pharmacokinetic Interactions Between Elbasvir or Grazoprevir and Methadone in Participants Receiving Maintenance Opioid Agonist TherapyHwa-Ping Feng, Zifang Guo, Luzelena Caro, et al.
Clinical Pharmacology in Drug Development|June 8, 2019
Assessment of Drug Interaction Potential Between the Hepatitis C Virus Direct-Acting Antiviral Agents Elbasvir/Grazoprevir and the Nucleotide Analog Reverse-Transcriptase Inhibitor Tenofovir Disoproxil FumarateHwa-Ping Feng, Zifang Guo, Luzelena Caro, et al.
Pageof 4